CD40LG and lung carcinoma: An historical seroprevalence study tested stored samples held on 959 patients in a lung cancer treatment trial from sites across Italy, detecting anti-RBD IgG and IgM antibodies to SARS-CoV-2 in September 2019 in 14% of samples [27].